-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text: Zhang Hu
Recently, transactions in the RNAi field have been active
On November 18, Novo Nordisk announced the acquisition of Dicerna for US$3.
As multinational pharmaceutical companies continue to deploy RNAi head companies, this once troubled technology will eventually make a comeback
RNAi mechanism
RNAi mechanismRNA interference (RNAi) is a biological process in which RNA molecules participate in the sequence-specific inhibition of gene expression by double-stranded RNA through translational or transcriptional inhibition
Two types of small ribonucleic acid (RNA) molecules—microRNA (miRNA) and small interfering RNA (siRNA)—are at the heart of RNA interference
The RNAi pathway exists in many eukaryotes, including animals, and is initiated by the enzyme Dicer, which cleaves long double-stranded RNA (dsRNA) molecules into short double-stranded fragments of approximately 21 nucleotides of siRNA
Figure 2.
RNAi and the Nobel Prize: There are successes and regrets
RNAi and the Nobel Prize: There are successes and regretsOn October 2, 2006, Stanford University professor Andrew Z.
2006 Nobel Prize in Medicine and Physiology
Subsequently, three scientists including the School of Biotechnology of the University of Cambridge in the United Kingdom expressed to the famous British magazine "Nature" that they regretted that scientists in the field of plant RNAi research were not included in the Nobel Prize for RNAi, and believed that this was a "grave" error" (serious error)
Industry leader:
Industry leader:Alnylam Pharmaceuticals
Alnylam PharmaceuticalsCurrently, 4 RNAi drugs have been approved by FDA or EMA, namely: Onpattro (patisiran), Givlaari (givosiran), Lumasiran (Oxlumo) and Inclisiran (Leqvio)
Without exception, the above four drugs that have been approved for marketing are all developed by Alnylam and its partner companies
Founded in 2002, Alnylam focuses on four areas: genetic diseases, liver infectious diseases, cardiometabolic diseases and central nervous system/ophthalmic diseases
Alnylam conjugated siRNA to N-Acetylgalactosamine (GalNAc) to form GalNAc-siRNA conjugates, in which GalNAc ligands can bind to the Asialoglycoprotein receptor (ASGPR) expressed by hepatocytes and targeted delivery of siRNA to hepatocytes
In order to improve the efficiency of gene silencing, Alnylam also used enhanced stabilization chemistry (ESC) technology to make some modifications to the RNA strand, and developed the ESC+ GalNAc-siRNA platform technology accordingly
Alnylam R&D pipeline
Another giant, Dicerna:
Another giant, Dicerna:Extensive cooperation with MNC
Extensive cooperation with MNCFounded in 2006, Dicerna is a Cambridge, Massachusetts-based company dedicated to the use of RNAi to treat disease
Dicerna's proprietary RNAi technology platform, called GalXCTM, silences disease genes in the liver
In 2018, Dicerna partnered with Alexion to co-develop subcutaneously delivered GalXC RNAi molecules targeting two complement pathway targets for the treatment of complement-mediated diseases
.
Dicerna is also working closely with Eli Lilly to develop new medicines in cardiometabolic disease, neurodegeneration and pain using the GalXCTMRNAi technology platform
.
summary
summaryIn China, leading companies in the field of RNAi include Sirnaomics, Ribo Bio, and Genkey Gene
.
Sirona Pharma utilizes pluripotent siRNA cocktail design and nanoparticle-enhanced therapeutic delivery to treat diseases, including anti-fibrosis and cancer therapy
.
Genkey Gene is mainly an RNAi service provider, providing RNAi product production and R&D services
.
Domestic RNAi therapy is still in its infancy.
In addition to STP705, a dual-target inhibitor based on small interfering nucleic acid from Sirona Pharmaceuticals, which is undergoing clinical trials in various diseases including cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis, The rest are still in the blank stage
.
RNAi technology specifically targets mRNA and modulates protein expression, and has great potential for silencing disease-related genes
.
Although the current RNAi therapy still faces many challenges in the process of clinical translation, we have reason to believe that with the continuous iteration of delivery vehicles or binding vehicles, the development of safe, precise and efficient delivery platforms will play an important role in promoting RNAi therapy.
.